NasdaqGM:CRVSBiotechs
Corvus Pharmaceuticals (CRVS) Is Up 229.4% After Strong Soquelitinib Data In Tough Dermatitis Patients
Corvus Pharmaceuticals recently reported positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of oral soquelitinib in moderate to severe atopic dermatitis, and confirmed plans to start a Phase 2 study in the first quarter of 2026.
The cohort 4 data are particularly interesting because they show clinical activity in patients who had previously failed systemic treatments, including dupilumab and JAK inhibitors, while maintaining a favorable safety profile...